European Subtype Report: Hodgkin Lymphoma
HL is primarily a curable cancer and with current treatments, 80% to 90% of patients can achieve permanent remission. The mainstay of treatment is multi-agent chemotherapy often in combination with radiation therapy. With high treatment responses, focus is now being made to improve long term morbidity issues.
Despite the success stories, there are still concerns:
- The long-term effects of treatment impacting overall quality of life. Patients are dealing with the effects of treatment for many years.
- Treating relapsed/refractory disease.
As well, there are discrepancies in incidence and mortality in Europe and continuing inequalities regarding treatment access.
While the overall survival rate for HL is good in relation to many other lymphomas, there is still work to do to ensure all patients can be effectively treated and enjoy a good quality of life post-treatment.
Click here to view or download the report.